



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

Patient Organisation Agreement

This Patient Organisation Agreement has been drawn up and entered into as of 31 May 2022 by and between

CSL Behring AB, Box 712, 182 17 Danderyd, SWEDEN, Reg. no. 556530-1974

And

Alfa 1 Danmark, Sangfuglestien 5, st. 2400 København NV,
formanden@alfa-1.dk

1. Background

Alpha-1-antitrypsin deficiency (ZZ) can cause lung disease, rare liver disease in adults and in some children also liver disease from birth.

The purpose of the alfa-1 Denmark is to optimize living conditions for people with Alpha-1 antitrypsin deficiency and create a forum for Alfa-1 patients and their relatives for mutual support, exchange of experience and knowledge acquisition. The aim is also to gain public understanding, acceptance and support to meet the needs of Alpha-1 patients and promote international cooperation on Alpha-1 antitrypsin deficiency.

CSL Behring operate in this field by improving treatment for patients living with alpha-1-antitrypsin deficiency (ZZ) and supports education and events in this therapeutic area.

2. Collaboration project

This agreement covers speaker's fee on behalf of CSL Behring in connection with an internal educational meeting with the Nordic CSL Behring team June 8, 2022. On behalf of Alfa 1 Danmark, Claus Astradsson is invited to give a lecture on the general patient experience of AATD and his engagement with the Danish alpha 1 patient association. Claus Astradsson will not talk about anything around treatment and will not attend any part of the meeting discussing treatment.

3. Finances

- 3.1 CSL Behring AB has undertaken to finance an internal lecture with 4000 DKK for educational purposes. Payment shall be made against separate invoice. The invoice shall be sent to DanderydPayables@cslbehring.com

State Pia Naested as reference on the invoice.

4. Transparency

- 4.1 Both Parties consent to the contents of this Agreement being shared with a third party.
- 4.2 Both parties consent to this agreement or a summary thereof being published on the company website and reported to ENLI in accordance with § 3 of the Patient Organizations Code regulated by the Ethical Committee for the Pharmaceutical Industry, ENLI.

5. Consultation, evaluation

- 5.1 Alfa 1 Danmark has appointed Claus Astradsson as their contact person in matters concerning this Agreement.



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

- 5.2 CSL Behring AB has appointed Pia Naested as their contact person in matters concerning this Agreement.
- 5.3 After completion of the project, the Parties shall jointly evaluate the internal lecture and their collaboration in relation to this project.

6. Agreement period and early termination

- 6.1 This Agreement is valid from 08/06/2022 until 08/06/2022.
- 6.2 If either party fails to fulfil their obligations pursuant to this Agreement and adjustments have not been made within thirty (30) days of the party being requested in writing to do so, the other party will be entitled to terminate the Agreement immediately.

7. Ethical rules and law

- 7.1 Ethical rules and national law apply to this agreement. Alfa 1 Danmark warrants that it will only use the funds received in accordance with national law and the Pharmaceutical Industry's Code of Ethics.
- 7.2 Alfa 1 Danmark may not refer to or make any representation relating to CSL Behring or its products or the co-operation under this agreement without CSL Behring's prior written approval. Alfa 1 Danmark shall submit all proposed materials mentioning CSL Behring, or referring to CSL Behring's products, or the co-operation under this agreement, to CSL Behring for written approval prior to publication or use.

8. Disputes

If a dispute should arise in conjunction with this Agreement, the Parties shall primarily attempt to resolve it through negotiation. In the event that the Parties are unable to reach an accord within thirty (30) days of the initial request for negotiation, the dispute shall be resolved in a Swedish Court.

9. E-signature

The Agreement may be executed by means of wet ink signatures or by using electronic signatures. If the Agreement is signed using electronic signatures, in making proof of this Agreement, an electronic copy of the Agreement will suffice. The Parties undertake not to dispute the validity of the Agreement based on the signatures being electronic.



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

This Agreement has been drawn up and signed in two (2) identical originals, of which each party has received an original.

Place and Date: Danderyd 220601
CSL Behring AB:

DocuSigned by:
Petter Olbe
.....181413637D10475.....

Name and title:
Petter Olbe,
Head of Marketing, Nordic Region

Place and Date: Stockholm Juni 1 2022
CSL Behring AB:

DocuSigned by:
Martin Tenlen
.....8BBB2BD230484A1.....

Name and title:
Martin Tenlen
General Manager, Nordic Region

Place and Date: 02-06-2022
Alfa 1 Danmark:

DocuSigned by:
Claus Astradsson
.....48E142EE6E1F4E9.....

Name and title:
Claus Astradsson